Zytoprotec

Develops cytoprotective therapies for the treatment of end-stage renal disease (ESRD) and other diseases

placeVienna, Vienna, Austria calendar_todayFounded 2007 groups10 employees language zytoprotec.com

Innovation

4 patent families (2 granted) — focus: Human necessities; filing pace accelerating. Cited 335 times.

YearFilings
20121
20132
20142
20151
20182
20191
20202
20221
20242

Investor mix

2 investors on record.

Investor typeCountShare
Other / undisclosed2100%
Coming soon